Ma, S., Tang, X., Long, L., Bai, X., Zhou, J., Duan, Z., . . . Dong, Z. (2021). Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: Results from two randomized studies. Oncoimmunology.
Chicago Style CitationMa, Si-Cong, et al. "Integrative Evaluation of Primary and Metastatic Lesion Spectrum to Guide Anti-PD-L1 Therapy of Non-small Cell Lung Cancer: Results From Two Randomized Studies." Oncoimmunology 2021.
Cita MLAMa, Si-Cong, et al. "Integrative Evaluation of Primary and Metastatic Lesion Spectrum to Guide Anti-PD-L1 Therapy of Non-small Cell Lung Cancer: Results From Two Randomized Studies." Oncoimmunology 2021.
Atenció: Aquestes cites poden no estar 100% correctes.